Cody R.Verified buyer
Jun 13, 2026
★★★★★
Fast shipping. Quality product.
Professionally packaged and arrived in just a few days. Will order again.
BLEND
37 sold in the last 24 hours
Order in 0h 0min for same-day shipping
99.57% Purity Verified
Third-Party Tested by Verum Analytics
Batch: BIL-CP10-01-2602Feb 4, 2026
Growth Hormone Peptides$95.00
CJC-1295 + Ipamorelin
CJC-1295 (No DAC) + Ipamorelin — the gold-standard GHRH + GHRP stack for natural growth-hormone release.
$95.00
99.57% Purity Verified
Third-Party Tested by Verum Analytics
Batch: BIL-CP10-01-2602Feb 4, 2026
+99% Purity
Third-Party Tested
COA Available
37 sold in the last 24 hours
Order in 0h 0min for same-day shipping
Buy More, Save More
QuantityPrice
Add 2 more for 15% off
Albert's Verdict
Stacking CJC-1295 without DAC with Ipamorelin gives you GHRH and GHS-R1a stimulation on two distinct pathways simultaneously. The pulse amplitude data on pituitary secretion from this combination is consistently stronger than either compound in isolation.
View COAArrives as lyophilized (powder) form
Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.
Secure Checkout256-bit SSL
99%+ PurityThird-Party Verified
Same-Day ShippingOrder by 2PM EST
Satisfaction Guarantee
Product Description
CJC-1295 + Ipamorelin is the most popular growth-hormone research stack, pairing a GHRH analog (Modified GRF 1-29) with a highly selective ghrelin-receptor agonist (Ipamorelin). The two peptides act on separate pituitary pathways, producing a stronger and cleaner pulsatile release of natural growth hormone than either peptide alone.
Extensively studied for body composition, recovery, sleep quality, and anti-aging applications. The Ipamorelin component is prized for its clean profile — no meaningful spikes in cortisol or prolactin — making this combo the preferred choice for researchers investigating natural GH optimization. For research use only. Not for human or veterinary consumption.
Technical Specifications
- Molecular Formula
- C152H252N44O42 + C38H49N9O5
- Molecular Weight
- 3367.97 + 711.85 g/mol
Frequently Researched Together
Commonly studied alongside in laboratory settings
Bundle total (3 items):$157.00
Verified reviews — CJC-1295 + Ipamorelin
5 verified buyers
★★★★★
5.0 / 5Kevin G.Verified buyer
Jun 11, 2026
★★★★★
Good product
fast shipping and product working as expected, I'm happy with the product.
Mandy K.Verified buyer
Jun 11, 2026
★★★★★
CJC 1295/IPA
This was one of our first peptides purchased and it has been excellent. Fast delivery and excellent product!!
Cruz U.Verified buyer
Jun 11, 2026
★★★★★
Trusted Partner
We were able to reconstitute and use it immediately. The level of purity is perfect and has made an impact.
Claudette A.Verified buyer
Jun 11, 2026
★★★★★
Fast shipping
Great quality!
Reviews are submitted by verified buyers via per-order tokenized links. Reviews are evaluated for product-focused content; any review containing therapeutic claims (cured, treats, healed, etc.) may be edited or hidden to maintain compliance with FDA and platform guidelines.
Learn More About This Peptide
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.
Research summary
CJC-1295 without DAC (Mod GRF 1-29) — clinical & mechanistic profile
Mod GRF 1-29 is a tetrasubstituted GHRH analog (Ala2, Gln8, Ala15, Leu27) with ~30-minute half-life (vs ~7 min native GHRH) due to DPP-IV resistance. Lacking DAC's albumin binding, it produces acute pulsatile GH release mimicking physiology, synergizing with GHRPs via complementary cAMP/Ca2+ pathways.
Research status
preclinical
Molecular weight
3367.95 g/mol
Molecular formula
C152H252N44O42
Studied applications
- •Preserved pulsatility: ~30 min half-life produces discrete GH spikes mimicking physiological patterns
- •DPP-IV resistance: Ala2 substitution blocks primary degradation enzyme, extending duration from ~7 to ~30 min
- •GHRP synergy: cAMP pathway (GHRH) + Ca2+/IP3 pathway (GHRPs) produce amplified GH pulses beyond additive effects
- •Flexible protocols: short duration allows timing with natural GH windows (sleep, exercise)
- •No albumin binding: lacks DAC moiety, enabling rapid clearance and pulsatile administration
Mechanisms of action
- •GHRHR full agonism: binds pituitary GHRH receptor, triggering Gs-protein coupling and adenylyl cyclase
- •cAMP/PKA pathway: adenylyl cyclase → cAMP → PKA activation → GH gene transcription and vesicle release
- •DPP-IV resistance: Ala2 substitution blocks dipeptidyl peptidase IV cleavage site
- •Synergistic signaling: complements GHRP Ca2+/IP3 pathway for amplified somatotroph activation
- •Dose-dependent peaks: produces sharp GH spikes 15-60 min post-injection, baseline by 180 min
Research constraints & safety notes
- •Not approved for human therapeutic use
- •Short half-life requires 2-3 daily injections for meaningful effects
- •No completed human clinical trials for this specific compound
- •Quality and purity of research compounds varies
- •Optimal dosing and timing protocols not established
Peer-reviewed references
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.